<DOC>
	<DOC>NCT00678743</DOC>
	<brief_summary>The primary objective of this trial is to assess the continued efficacy of Omacor co-administered with simvastatin for lowering non-high-density lipoprotein cholesterol (non-HCL-C) levels.</brief_summary>
	<brief_title>An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin</brief_title>
	<detailed_description>The present trial is an open-label, uncontrolled extension to the previous trial (PRV-06009) which utilized a randomized,double-blind, two-period crossover design with eight clinic vists. The current trial consists of nine clinic visits over 104 weeks. There will be two treatment periods in this study: - Phase I: All subjects will receive simvastatin 80 md/d plus Omacor 4 g/d for the first six weeks of the trial. - Phase II: All subjects will receive simvastatin (at a dose to be determined at the discretion of the Investigator) plus Omacor 4 g/d for the remainder of the treatment period.</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Must have met all relevant inclusion/exclusion criteria prior to and throughout the previous doubleblind study (PRV06009) Must have completed the previous doubleblind study to week 12. Provide written informed consent and authorization for protected health information Study drug compliance less than 50% in PRV06009 Any ongoing serious adverse event from PRV06009</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>omega 3</keyword>
</DOC>